Abby Hardy, Author at BioTuesdays

Markets

Dyadic International approved for uplisting to NASDAQ

The common stock of Dyadic International (OTCQX:DYAI) was approved for listing on The Nasdaq Capital Market, beginning on April 17, under the trading symbol, DYAI. “Our listing on the NASDAQ is a major milestone...

April 15, 2019

Developments

OPKO reports additional Phase 2 data for Type 2 diabetes and obesity candidate

OPKO Health (NASDAQ:OPK) reported additional results from its Phase 2 dose escalation trial of OPK-88003, a once-weekly oxyntomodulin for the treatment of Type 2 diabetes and obesity. OPK-88003 is a dual GLP-1/glucagon...

April 12, 2019

Developments

Eiger presents positive Phase 2 results for hepatitis D candidate

Eiger BioPharmaceuticals (NASDAQ:EIGR) presented positive post-treatment results from its Phase 2 trial of lambda interferon monotherapy (LIMT) in patients with chronic hepatitis D virus (HDV). The study enrolled 33...

April 12, 2019

Developments

ContraVir Pharma to present CRV431 Phase 1 data at Intl Liver Congress

ContraVir Pharmaceuticals (NASDAQ:CTRV) will present a poster on a Phase 1 single ascending dose study of its drug candidate, CRV431, at the International Liver Congress, taking place in Vienna, Austria from April 10-to...

April 11, 2019

Developments

Avinger’s image-guided atherectomy system gets FDA pre-marketing clearance

Avinger’s (NASDAQ:AVGR) Pantheris SV (small vessel) image-guided atherectomy system, indicated for the diagnosis and treatment peripheral artery disease (PAD), has received 510(k) clearance from the FDA. Atherectomy is...

April 10, 2019

Developments

Provention Bio begins Phase 3 trial of teplizumab for recent onset Type 1 diabetes

Provention Bio (NASDAQ:PRVB) has dosed the first patient in its Phase 3 clinical trial of teplizumab for Type 1 diabetes (T1D). The trial will determine whether teplizumab, an anti-CD3 monoclonal antibody, slows the...

April 9, 2019

Developments

Valeritas V-Go reports greater A1C reduction with 24% less daily insulin

Valeritas Holdings’ (NASDAQ:VLRX) V-Go wearable insulin delivery device significantly lowered Type 2 diabetes (T2D) patients’ average A1C levels, compared with those using standard insulin treatment. Valeritas’ V-GoAL...

April 8, 2019

Developments

Trovagene AML drug generates positive interim Phase 1b/2 data

Trovagene (NASDAQ:TROV) announced positive interim data from its Phase 1b/2 dose escalation trial of onvansertib, in combination with standard-of-care chemotherapy, in acute myeloid leukemia (AML) patients. Three of six...

April 5, 2019

Developments

FDA accepts Homology’s IND for Phase 1/2 study of PKU gene therapy

Homology Medicines (NASDAQ:FIXX) received FDA clearance to commence its Phase 1/2 study of HMI-102 in adults with phenylketonuria (PKU), a rare genetic disease affecting metabolism. Individuals with PKU lack the...

April 5, 2019

Developments

Ziopharm glioblastoma program gets FDA fast track designation

Ziopharm Oncology’s (NASDAQ:ZIOP) controlled IL-12 program received FDA fast track designation for the treatment of recurrent or progressive glioblastoma multiforme (rGBM) in adults. Controlled IL-12 consists of IL-12...

April 3, 2019

Author - Abby Hardy

Dyadic International approved for uplisting to NASDAQ

OPKO reports additional Phase 2 data for Type 2 diabetes and obesity candidate

Eiger presents positive Phase 2 results for hepatitis D candidate

ContraVir Pharma to present CRV431 Phase 1 data at Intl Liver Congress

Avinger’s image-guided atherectomy system gets FDA pre-marketing clearance

Provention Bio begins Phase 3 trial of teplizumab for recent onset Type 1 diabetes

Valeritas V-Go reports greater A1C reduction with 24% less daily insulin

Trovagene AML drug generates positive interim Phase 1b/2 data

FDA accepts Homology’s IND for Phase 1/2 study of PKU gene therapy

Ziopharm glioblastoma program gets FDA fast track designation

Subscribe